INTRODUCTION: We compared subject-specific white matter (SSWM) and whole cerebellum (CBL) reference regions for power to detect longitudinal change in amyloid positron emission tomography signal. METHODS:Positive florbetapir positron emission tomography scans were analyzed from participants (66 placebo treated and 63 solanezumab treated) with mild dementia caused by Alzheimer's disease from the EXPEDITION and EXPEDITION2 studies. For comparison to CBL, a second normalization was performed on longitudinal data using an SSWM correction factor (SSWM normalization ratio [SSWMnr]). Analysis of covariance assessed baseline to 18-month change between treatment with solanezumab and placebo. Sample and effect size estimations provided magnitude of observed treatment changes. RESULTS: Longitudinal percent change between placebo and solanezumab using CBL was not significant (P = .536) but was significant for SSWMnr (P = .042). Compared with CBL, SSWMnr technique increased the power to detect a treatment difference, more than tripling the effect size and reducing the sample size requirements by 85% to 90%. DISCUSSION: Adjusting longitudinal standardized uptake value ratios with an SSWM reference region in these antiamyloid treatment trials increased mean change detection and decreased variance resulting in the substantial improvement in statistical power to detect change.
RCT Entities:
INTRODUCTION: We compared subject-specific white matter (SSWM) and whole cerebellum (CBL) reference regions for power to detect longitudinal change in amyloid positron emission tomography signal. METHODS: Positive florbetapir positron emission tomography scans were analyzed from participants (66 placebo treated and 63 solanezumab treated) with mild dementia caused by Alzheimer's disease from the EXPEDITION and EXPEDITION2 studies. For comparison to CBL, a second normalization was performed on longitudinal data using an SSWM correction factor (SSWM normalization ratio [SSWMnr]). Analysis of covariance assessed baseline to 18-month change between treatment with solanezumab and placebo. Sample and effect size estimations provided magnitude of observed treatment changes. RESULTS: Longitudinal percent change between placebo and solanezumab using CBL was not significant (P = .536) but was significant for SSWMnr (P = .042). Compared with CBL, SSWMnr technique increased the power to detect a treatment difference, more than tripling the effect size and reducing the sample size requirements by 85% to 90%. DISCUSSION: Adjusting longitudinal standardized uptake value ratios with an SSWM reference region in these antiamyloid treatment trials increased mean change detection and decreased variance resulting in the substantial improvement in statistical power to detect change.
Authors: Yun Zhou; Shaney Flores; Syahir Mansor; Russ C Hornbeck; Zhude Tu; Joel S Perlmutter; Beau Ances; John C Morris; Robert J Gropler; Tammie L S Benzinger Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-18 Impact factor: 9.236
Authors: Cyrille Sur; Katarzyna Adamczuk; David Scott; James Kost; Mehul Sampat; Christopher Buckley; Gill Farrar; Ben Newton; Joyce Suhy; Idriss Bennacef; Michael F Egan Journal: Mol Imaging Biol Date: 2022-07-07 Impact factor: 3.488
Authors: Christopher M Lee; Heidi I L Jacobs; Marta Marquié; John A Becker; Nicolas V Andrea; David S Jin; Aaron P Schultz; Matthew P Frosch; Teresa Gómez-Isla; Reisa A Sperling; Keith A Johnson Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Theresa M Harrison; Renaud La Joie; Anne Maass; Suzanne L Baker; Kaitlin Swinnerton; Laura Fenton; Taylor J Mellinger; Lauren Edwards; Julie Pham; Bruce L Miller; Gil D Rabinovici; William J Jagust Journal: Ann Neurol Date: 2019-01-17 Impact factor: 10.422
Authors: Stephen Salloway; Lee A Honigberg; William Cho; Michael Ward; Michel Friesenhahn; Flavia Brunstein; Angelica Quartino; David Clayton; Deborah Mortensen; Tobias Bittner; Carole Ho; Christina Rabe; Stephen P Schauer; Kristin R Wildsmith; Reina N Fuji; Shehnaaz Suliman; Eric M Reiman; Kewei Chen; Robert Paul Journal: Alzheimers Res Ther Date: 2018-09-19 Impact factor: 6.982
Authors: Rainer Hinz; Hector Chinoy; James B Lilleker; Richard Hodgson; Mark Roberts; Karl Herholz; James Howard Journal: Ann Rheum Dis Date: 2019-02-13 Impact factor: 19.103
Authors: Mara Ten Kate; Silvia Ingala; Adam J Schwarz; Nick C Fox; Gaël Chételat; Bart N M van Berckel; Michael Ewers; Christopher Foley; Juan Domingo Gispert; Derek Hill; Michael C Irizarry; Adriaan A Lammertsma; José Luis Molinuevo; Craig Ritchie; Philip Scheltens; Mark E Schmidt; Pieter Jelle Visser; Adam Waldman; Joanna Wardlaw; Sven Haller; Frederik Barkhof Journal: Alzheimers Res Ther Date: 2018-10-30 Impact factor: 6.982